# A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100mcg/Blister Oral Inhalation Powder/GSK in Patients With Asthma

> **NCT04665895** · PHASE3 · COMPLETED · sponsor: **Respirent Pharmaceuticals Co Ltd.** · enrollment: 451 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Fluticasone propionate 100 mcg/blister oral inhalation powder/Respirent Pharmaceuticals
- **DRUG:** FLOVENT DISKUS® 100 mcg/blister oral inhalation powder/GSK
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04665895
- **Lead sponsor:** Respirent Pharmaceuticals Co Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-09
- **Primary completion:** 2021-08-13
- **Final completion:** 2022-02-22
- **Target enrollment:** 451 (ACTUAL)
- **Last updated:** 2023-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04665895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04665895, "A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100mcg/Blister Oral Inhalation Powder/GSK in Patients With Asthma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04665895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*